COVID-19: a crash test for biomedical publishing?

The effect of COVID-19 on biomedical publishing (BP) (i.e. scientific biomedical periodicals continuously published by research communities or commercial publishers) has not been deeply explored. To estimate the immediate COVID-19 impact on BP, we have assessed <underline>P</underline>ub<underline>M</underline>ed-<underline>i</underline>ndexed <underline>a</underline>rticles about <underline>C</underline>OVID-19 (PMIAC) from December 2019 to April 2020. PMIAC have been classified according to publication date, country, and journals for evaluation of time-, region- and scientometric-dependant impact of COVID-19 on BP and have been curated manually (i.e. each entry has been individually analyzed). PMIAC analysis reflects geographic and temporal parameters of outbreak spread. A major BP problem is related to the fact that only 40% of articles report/review/analyze data. Another BP weakness is the clusterization of “highly-trusted” publications according to countries of origin and “highly impacting” journals. Finally, a problem highlighted by COVID-19 crisis is the increased specification of biomedical research. To solve the problem, analytical reviews integrating data from different areas of biology and medicine are required. The data on PMIAC suggest priority of “what is published” over “where it is published” and “who are the authors”. We believe that our brief analysis may help to shape forthcoming BP to become more effective in solving immediate problems resulted from global threats.